Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19
Abstract Background This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylacti...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Virology Journal |
| Online Access: | https://doi.org/10.1186/s12985-025-02814-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725546590633984 |
|---|---|
| author | Mostafa Hossam El Din Moawad Abdallah Abbas Haneen Sabet Mohamed Ahmed Zanaty Abdullah Ashraf Hamad Ayoub Rezkallah Osama Ballut Taha Fayad Mona Mahmoud Elsakka Francis Eshun Hussien Ahmed H. Abdelgawad |
| author_facet | Mostafa Hossam El Din Moawad Abdallah Abbas Haneen Sabet Mohamed Ahmed Zanaty Abdullah Ashraf Hamad Ayoub Rezkallah Osama Ballut Taha Fayad Mona Mahmoud Elsakka Francis Eshun Hussien Ahmed H. Abdelgawad |
| author_sort | Mostafa Hossam El Din Moawad |
| collection | DOAJ |
| description | Abstract Background This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylactic strategies are critical. Methods Following PRISMA guidelines, we comprehensively searched electronic databases, including PubMed, Scopus, Web of Science, and Embase, up to June 22, 2024. We included studies assessing tixagevimab-cilgavimab's impact on SARS-CoV-2 infection rates, hospitalization, ICU admissions, and/or mortality among immunocompromised patients. Data synthesis and analysis were conducted using RevMan and Open-Meta Analyst software. Results Analyzing data from 36 studies involving 28,950 patients, tixagevimab-cilgavimab significantly reduced SARS-CoV-2 infection rates by 4.37%, hospitalization by 0.8%, and mortality by 0.5%. Compared to no prophylaxis, the drug combination showed a notable reduction in SARS-CoV-2 infection (OR = 0.33, 95% CI: 0.22–0.50), hospitalization (OR = 0.24, 95% CI: 0.15–0.39), and mortality (OR = 0.33, 95% CI: 0.16–0.66), exhibiting a favorable safety and efficacy profile. During the Omicron surge, tixagevimab-cilgavimab consistently reduced infection risk (OR = 0.32, 95% CI: 0.17–0.58). Conclusion Tixagevimab-cilgavimab offers a significant protective effect against COVID-19, including Omicron variants, in immunocompromised patients, underscoring its role as an effective pre-exposure prophylaxis. Future studies should further explore its efficacy across different SARS-CoV-2 variants and potential synergies with vaccination efforts. |
| format | Article |
| id | doaj-art-4b9d629b890549d5af3d35eba5250d40 |
| institution | DOAJ |
| issn | 1743-422X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj-art-4b9d629b890549d5af3d35eba5250d402025-08-20T03:10:27ZengBMCVirology Journal1743-422X2025-06-0122111710.1186/s12985-025-02814-7Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19Mostafa Hossam El Din Moawad0Abdallah Abbas1Haneen Sabet2Mohamed Ahmed Zanaty3Abdullah Ashraf Hamad4Ayoub Rezkallah5Osama Ballut6Taha Fayad7Mona Mahmoud Elsakka8Francis Eshun9Hussien Ahmed H. Abdelgawad10Faculty of Pharmacy Clinical Department, Alexandria UniversityFaculty of Medicine, Al-Azhar UniversityFaculty of Medicine, South Valley UniversityFaculty of Medicine, South Valley UniversityFaculty of Medicine, Menoufia UniversityFaculty of Medicine, Algiers UniversityFaculty of Medicine, Kasr Alainy, Cairo UniversityFaculty of Oral and Dental Medicine, Sinai UniversityFaculty of Pharmacy, Damanhour UniversityCenter for Cancer and Blood Disorders, Phoenix Children’s HospitalCenter for Cancer and Blood Disorders, Phoenix Children’s HospitalAbstract Background This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylactic strategies are critical. Methods Following PRISMA guidelines, we comprehensively searched electronic databases, including PubMed, Scopus, Web of Science, and Embase, up to June 22, 2024. We included studies assessing tixagevimab-cilgavimab's impact on SARS-CoV-2 infection rates, hospitalization, ICU admissions, and/or mortality among immunocompromised patients. Data synthesis and analysis were conducted using RevMan and Open-Meta Analyst software. Results Analyzing data from 36 studies involving 28,950 patients, tixagevimab-cilgavimab significantly reduced SARS-CoV-2 infection rates by 4.37%, hospitalization by 0.8%, and mortality by 0.5%. Compared to no prophylaxis, the drug combination showed a notable reduction in SARS-CoV-2 infection (OR = 0.33, 95% CI: 0.22–0.50), hospitalization (OR = 0.24, 95% CI: 0.15–0.39), and mortality (OR = 0.33, 95% CI: 0.16–0.66), exhibiting a favorable safety and efficacy profile. During the Omicron surge, tixagevimab-cilgavimab consistently reduced infection risk (OR = 0.32, 95% CI: 0.17–0.58). Conclusion Tixagevimab-cilgavimab offers a significant protective effect against COVID-19, including Omicron variants, in immunocompromised patients, underscoring its role as an effective pre-exposure prophylaxis. Future studies should further explore its efficacy across different SARS-CoV-2 variants and potential synergies with vaccination efforts.https://doi.org/10.1186/s12985-025-02814-7 |
| spellingShingle | Mostafa Hossam El Din Moawad Abdallah Abbas Haneen Sabet Mohamed Ahmed Zanaty Abdullah Ashraf Hamad Ayoub Rezkallah Osama Ballut Taha Fayad Mona Mahmoud Elsakka Francis Eshun Hussien Ahmed H. Abdelgawad Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 Virology Journal |
| title | Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 |
| title_full | Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 |
| title_fullStr | Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 |
| title_full_unstemmed | Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 |
| title_short | Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19 |
| title_sort | unveiling protection a meta analysis of tixagevimab cilgavimab prophylaxis in 28 950 transplant recipients and immunocompromised patients against covid 19 |
| url | https://doi.org/10.1186/s12985-025-02814-7 |
| work_keys_str_mv | AT mostafahossameldinmoawad unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT abdallahabbas unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT haneensabet unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT mohamedahmedzanaty unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT abdullahashrafhamad unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT ayoubrezkallah unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT osamaballut unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT tahafayad unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT monamahmoudelsakka unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT franciseshun unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 AT hussienahmedhabdelgawad unveilingprotectionametaanalysisoftixagevimabcilgavimabprophylaxisin28950transplantrecipientsandimmunocompromisedpatientsagainstcovid19 |